Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

Exclusion Criteria

• •Evidence of complete or partial bowel obstruction
• •Subjects with primary central nervous system (CNS) tumor or CNS tumor involvement. However, subjects with metastatic CNS tumors may participate in this study if the patient is:
• •* \> 4 weeks from prior therapy completion
• •* Clinically stable with respect to the CNS tumor at the time of study entry
• •* Not receiving steroid therapy in treating CNS tumor or CNS tumor involvement
• •* Not receiving anti-convulsive medications (that were started for brain metastases)
• •Need of total parenteral nutrition
• •Allergic to any of anti-PD-1/PD-L1 monoclonal antibody (mAb) intended to receive
• •Prior exposure to plinabulin
• •Pregnancy or lactation
• •Radiation (except planned or ongoing palliative radiation to bone outside of the region of measurable disease) =\< 3 weeks prior to study drug administration date
• •Chemotherapy, or immunotherapy or any other systemic anticancer therapy =\< 3 weeks prior to study drug administration date except anti-PD-1/PD-L1 mAb mono or combination therapy
• •Diagnosis or recurrence of invasive cancer other than the present cancer within 3 years (except basal or squamous cell carcinoma of the skin that has been definitively treated)
• •Major surgery within four weeks before consent date
• •Unstable cardiovascular function or active cardiac disease:
• •* Symptomatic ischemia (chest pain of cardiac origin),or
• •* Uncontrolled clinically significant conduction abnormalities (e.g. ventricular tachycardia on antiarrhythmics are excluded; 1st degree AV block or asymptomatic Left anterior fascicular block (LAFB)/ right bundle branch block (RBBB) will not be excluded),or
• •* Congestive heart failure (CHF) of New York Heart Association (NYHA) class \>= 3, or
• •* Myocardial infarction (MI) within 3 months of consent date
• •Uncontrolled active infection requiring parenteral antibiotics, antivirals, or antifungals within one week prior to the first dose. Active infection with concurrent treatment is acceptable only if the patient is clinically stable
• •Subject is known to be positive for human immunodeficiency virus (HIV), hepatitis B or hepatitis C
• •Significantly diseased (as determined by the PI or treating physician) or obstructed gastrointestinal tract or uncontrolled vomiting or diarrhea. Presence of ileus or other significant gastrointestinal disorder known to predispose to ileus or chronic bowel hypomotility
• •Treatment with an investigational anti-cancer study drug within 3 weeks prior to study drug administration date
• •Concurrent therapy with approved or investigational anticancer therapeutics
• •Medical, psychological or social conditions that may interfere with the patient's participation in the study or evaluation of the study results
• •Men whose partner is a woman of child-bearing potential, (i.e. biologically able to conceive), and who is not employing two forms of highly effective contraception. Highly effective contraception (e.g. male condom with spermicide, diaphragm with spermicide, intra-uterine device) must be used by both sexes during the study and must be continued for 5 months following the last dose of atezolizumab or nivolumab, for 4 months after the last dose of pembrolizumab, and for 3 months after last dose of durvalumab and avelumab, and for 3 months after your last dose of plinabulin. Women of child-bearing potential is defined as sexually mature women who are not surgically sterile or who have not been naturally postmenopausal for at least 12 consecutive months (e.g., who has had menses any time in the preceding 12 consecutive months)